Eli Lilly and Company $LLY Shares Bought by BankPlus Trust Department

BankPlus Trust Department increased its holdings in Eli Lilly and Company (NYSE:LLY) by 2.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,574 shares of the company’s stock after purchasing an additional 189 shares during the quarter. Eli Lilly and Company accounts for about 1.7% of BankPlus Trust Department’s holdings, making the stock its 7th largest holding. BankPlus Trust Department’s holdings in Eli Lilly and Company were worth $5,904,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in LLY. Canopy Partners LLC raised its holdings in shares of Eli Lilly and Company by 37.9% during the second quarter. Canopy Partners LLC now owns 1,556 shares of the company’s stock valued at $1,213,000 after acquiring an additional 428 shares during the last quarter. High Note Wealth LLC raised its holdings in shares of Eli Lilly and Company by 0.4% during the second quarter. High Note Wealth LLC now owns 3,184 shares of the company’s stock valued at $2,482,000 after acquiring an additional 14 shares during the last quarter. SGL Investment Advisors Inc. raised its holdings in shares of Eli Lilly and Company by 9.8% during the second quarter. SGL Investment Advisors Inc. now owns 438 shares of the company’s stock valued at $341,000 after acquiring an additional 39 shares during the last quarter. Shell Asset Management Co. raised its holdings in shares of Eli Lilly and Company by 27.1% during the second quarter. Shell Asset Management Co. now owns 44,237 shares of the company’s stock valued at $34,484,000 after acquiring an additional 9,433 shares during the last quarter. Finally, Prasad Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 65.1% during the second quarter. Prasad Wealth Partners LLC now owns 1,032 shares of the company’s stock valued at $805,000 after acquiring an additional 407 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Guggenheim reduced their target price on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. HSBC upped their price target on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Finally, Berenberg Bank restated a “hold” rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $938.94.

Eli Lilly and Company Trading Down 0.1%

Shares of Eli Lilly and Company stock opened at $844.30 on Wednesday. The firm has a market capitalization of $799.09 billion, a price-to-earnings ratio of 55.18, a PEG ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a 50 day moving average of $736.97 and a 200 day moving average of $766.03.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO David A. Ricks purchased 1,632 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock valued at $2,894,841 in the last ninety days. Company insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.